Adjuvant therapy with trastuzumab for early-stage breast cancer: 12 or 24 months (based on ESMO data, Vienna, october, 2012)
- Authors: Zhukova L.G1, Lichinitser M.R1
-
Affiliations:
- Issue: No 18 (2012)
- Pages: 69-71
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280006
- ID: 280006
Cite item
Open Access
Access granted
Abstract
Final analysis of HERA trial (median follow-up eight years) confirmed one year of trastuzumab treatment as standard of care in early-stage HER2-positive breast cancer.
Full Text
References
Supplementary files
